



PRESS RELEASE

Making operations safer with digitized data acquisition and AI

Complications can always occur during operations, sometimes resulting in death. A new project called KIPeriOP aims to minimize the risk of such complications. The project is based on digitized decision guidelines and self-learning algorithms intended to provide reliable risk assessment based on individual patient data. What is the probability that certain complications will occur, and how might they be avoided? The project is coordinated by Prof. Dr. Anja Hennemuth from the Fraunhofer Institute for Digital Medicine MEVIS and Prof. Dr. Patrick Meybohm from the University Hospital of Würzburg. Clinicians from the Asklepios Medical School GmbH, the University Hospital Frankfurt and the Charité – Universitätsmedizin Berlin are involved. They are working together with experts from the fields of AI, user guidance, ethics, and health economics.

More than 16 million operations are performed every year in Germany. Complications occur time and again, and sometimes lead to death. In Western industrialized nations, 0.4 to 0.8 percent of patients die during or following an operation. Hospitals often try to reduce this by accounting for possible risk factors. What are a patient's accompanying diseases? What medications are being taken? What complications might arise, and how could these be minimized?

There are already guidelines to assist medical personnel during risk assessment. They list, for instance, the type and number of useful preliminary examinations. But in the real world, these guidelines aren't always easy to apply. The guidelines are complex documents and employing them requires considering a wealth of information that is sometimes not easy to obtain.

Algorithms that assess risk

Here is where the KIPeriOP research project, carried out by an interdisciplinary consortium, comes into play. The goal is to develop a clinical decision support (CDS) system. Software developed by publisher Börm-Bruckmeyer will gather possible risk factors on a patient-specific and guideline-compliant basis, correlate them with each other, and deliver a risk assessment. How likely is it that a particular patient experiences serious complication during or after surgery? "Based on this risk assessment, clinicians can decide, for example, whether additional examinations are needed and what can be done to prepare the patient optimally for surgery," explains Meybohm.

As much patient information as possible should be fed into the CDS system, including laboratory values, medication schedule, vital signs, and information about lifestyle habits. In addition to considering the guideline, KIPeriOP will employ artificial intelligence (AI) to analyze the digitally captured data. Learning algorithms will search out patterns and correlations that expose which groups of risk factors are likely to lead to which complications. With the help of AI, for example, it might be easier to recognize when a patient suffers from undiagnosed cardiac insufficiency and therefore an increased risk of surgery.

Redaktion & Kontakt

Bianka Hofmann | Fraunhofer-Institut für Digitale Medizin MEVIS | +49 421 218 59231 Max-von-Laue-Str. 2 | 28359 Bremen | Germany | www.mevis.fraunhofer.de bianka.hofmann@mevis.fraunhofer.de

Susanne Just | Universtitätklinikum Würzburg | +49 931 201 59447 Josef-Schneider-Straße 2, Haus D3 | 97080 Würzburg Just_S@ukw.de

Bremen, Würzburg; June 18, 2021 Page 1|3



In the project, various AI methods will be tested to discover an optimal model. To work reliably, the algorithms must first be trained by feeding them with many data sets from real preliminary examinations and surgical procedures. The four clinical project partners will collect these data sets. "We're not just gathering data that's already available; we can adapt the data collection specifically to our needs," says Meybohm. "We hope that this will increase the relevance and accuracy of the algorithms and recommended actions."

Trust built upon transparent operation

A great challenge in developing the CDS system is its usability. "We have to design the Albased solution so that enhances physicians' work and is not seen as a burden," emphasizes Hennemuth, who also holds a professorship at the Charité – Universitätsmedizin Berlin. "The essential trust in new technology can only happen if we clearly present how and with what certainty the algorithms come to their results."The Al should not act as a black box: it should make uncertainties and possible sources of error transparent. Development will feature close coordination with the project's clinical partners and an ethics team at RWTH Aachen University.

In the long term, the CDS system could even provide another benefit: It might be able to detect previously unidentified data relationships between input information and frequency of complication. This could help unearth previously unknown risk factors. These results could be integrated into upcoming guidelines and help make operations even safer. The economic impact and possible new opportunities for healthcare are also being investigated in the project: model calculations are being performed by the Technical University of Munich.

KIPeriOP

is a research project funded by the German Federal Ministry of Health with 1.5 million euros until September 2023. It aims to improve perioperative risk management and decrease perioperative mortality and permanent damage. The interdisciplinary consortium is coordinated by the University Hospital of Würzburg and Fraunhofer MEVIS. Physicians from University Hospital of Würzburg (Dr. J. Stumpner, Dr. P. Bendz, Dr. A. Englert), Asklepios Medical School GmbH (Prof. Dr. A. Ghanem), Frankfurt University Hospital (Prof. Dr. Dr. K. Zacharowski, Dr. P. Booms), and Charité – Universitätsmedizin Berlin (Prof. Dr. C. Spies, Prof. Dr. F. Balzer) perform patient treatment, implementation research, development and enhancement of machinereadable protocols, and real-time validation. Fraunhofer MEVIS (Dr. M. Westphal, M. Hüllebrand, S. Archipovas) is responsible for developing and evaluating innovative and accessible AI modules for clinical decision support. Börm Bruckmeier Verlag (N. Blanck, Dr. P. Börm) is responsible for CDS development and product approval. The research topic of applied ethics at RWTH Aachen University (Prof. Dr. S. Nagel) is analyzing and designing the ethical requirements for digital clinical decision support. The Department of Sports and Health Sciences at the Technical University of Munich (Prof. Dr. L. Sundmacher, A. Flothow) is investigating economic effects of clinical decision support.



Bremen, Würzburg; June 18, 2021 Page 2|3

Editor & Contact Bianka Hofmann | Fraunhofer-Institut für Digitale Medizin MEVIS | +49 421 218 59231 Max-von-Laue-Str. 2 | 28359 Bremen | Germany | www.mevis.fraunhofer.de bianka.hofmann@mevis.fraunhofer.de

Susanne Just | Universtitätklinikum Würzburg | +49 931 201 59447 Josef-Schneider-Straße 2, Haus D3 | 97080 Würzburg | Germany | Just_S@ukw.de





Bremen, Würzburg; June 18, 2021 Page 3|3

Embedded in a worldwide network of clinical and academic partners, **Fraunhofer MEVIS** develops real-world software solutions for image and data supported early detection, diagnosis, and therapy. Strong focus is placed on cancer as well as diseases of the circulatory system, brain, breast, liver, and lung. The goal is to detect diseases earlier and more reliably, tailor treatments to each individual, and make therapeutic success more measurable. In addition, the institute develops software systems for industrial partners to undertake image-based studies to determine the effectiveness of medicine and contrast agents. To reach its goals, Fraunhofer MEVIS works closely with medical technology and pharmaceutical companies, providing solutions for the entire chain of development from applied research to certified medical products www.mevis.fraunhofer.de

The Fraunhofer-Gesellschaft, headquartered in Germany, is the world's leading applied research organization. With its focus on developing key technologies that are vital for the future and enabling the commercial exploitation of this work by business and industry, Fraunhofer plays a central role in the innovation process. As a pioneer and catalyst for groundbreaking developments and scientific excellence, Fraunhofer helps shape society now and in the future. Founded in 1949, the Fraunhofer-Gesellschaft currently operates 75 institutes and research institutions throughout Germany. The majority of the organization's 29,000 employees are qualified scientists and engineers, who work with an annual research budget of 2.8 billion euros. Of this sum, 2.4 billion euros are generated through contract research. www.fraunhofer.de

The University Hospital Würzburg (UKW) is the only supramaximal care hospital in the Lower Franconia region covering a catchment area of over one million inhabitants. With more than 1,400 beds, the University Hospital Würzburg currently treats nearly 69,000 inpatients and day patients and more than 249,000 outpatients per year. Under the motto Top Medicine and Top Research for the benefit of our patients, science and patient treatment are so closely intertwined that all patients benefit from the most up-to-date therapy standards. In addition, many of the therapeutic concepts have a nationwide, and in some cases even worldwide, appeal. Its research is also of international standard. Around 7,300 employees guarantee patient-centered medicine and care in accordance with recognized quality standards: The services provided by the University Hospital Würzburg have been certified and awarded many times. In addition, the entire University Hospital Würzburg is certified according to the KTQ guidelines. www.ukw.de